Table 1 Patient characteristics.
| Lymphoma subtype | Total number | Male | Female | Bone marrow involvement | Disease‐related deaths | Median survival (months) | Mean survival (months) | Mean follow‐up (range) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| n | Mean age | n | Mean age | |||||||
| De novo DLBCL | 111 | 56 | 64 | 45 | 66 | 24/94 (25%) | 42/96 (44%) | 26 | 63 | 41 (1–177) |
| Secondary DLBCL | 18 | 11 | 59 | 7 | 69 | 9/17 (53%) | 11/16 (69%) | 19 | 51 | 44 (3–130) |
| MCL | 19 | 14 | 59 | 5 | 66 | 8/12 (67%) | 7/9 (78%) | 20 | 35 | 26 (4–107) |
| FL G3 | 15 | 5 | 52 | 10 | 57 | 2/8 (25%) | 1/9 (10%) | Not reached | 55 | 49 (2–105) |
| FL G1&2 | 70 | 32 | 57 | 38 | 57 | 26/51 (51%) | 11/47 (23%) | Not reached | 94 | 57 (8–129) |
| SLL/CLL | 38 | 28 | 62 | 10 | 71 | 21/22 (96%) | 9/20 (45%) | 82 | 76 | 68 (2–132) |
DLBCL, diffuse large B cell lymphoma; FL G, follicular lymphoma grade; MCL, mantle cell lymphoma; SLL/CLL, small lymphocytic lymphoma/chronic lymphocytic leukaemia.